Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, et al. Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial. Cardiovascular diabetology. 2023. 22. 1. 143-143
Hidenori Yoshii, Tomoya Mita, Naoto Katakami, Yosuke Okada, Takeshi Osonoi, Katsumi Aso, Akira Kurozumi, Satomi Wakasugi, Fumiya Sato, Ryota Ishii, et al. The importance of continuous glucose monitoring-derived metrics beyond HbA1c for optimal individualized glycemic control. The Journal of clinical endocrinology and metabolism. 2022. 107. 10. e3990-e4003
Akira Kurozumi, Yosuke Okada, Tomoya Mita, Satomi Wakasugi, Naoto Katakami, Hidenori Yoshii, Kazuko Kanda, Keiko Nishida, Shinichiro Mine, Yoshiya Tanaka, et al. Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus. Diabetes research and clinical practice. 2022. 186. 109836-109836
Fumi Uemura, Yosuke Okada, Tomoya Mita, Keiichi Torimoto, Satomi Wakasugi, Naoto Katakami, Hidenori Yoshii, Koji Matsushita, Keiko Nishida, Nobuo Inokuchi, et al. Risk Factor Analysis for Type 2 Diabetic Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study. Diabetes technology & therapeutics. 2022
Keiichi Torimoto, Yosuke Okada, Yasunori Sato, Yoshiya Tanaka. Addition of Canagliflozin to Insulin Improves Glycemic Control and Reduces Insulin Dose in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. DIABETES. 2019. 68